StockNews.AI
ITRM
StockNews.AI
127 days

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

1. ITRM presented findings on antibiotic efficacy at the ECCMID 2025. 2. Poster focused on age impact on uUTI treatment effectiveness. 3. ORLYNVAH™ has FDA approval for treating specific uUTIs. 4. Sulopenem shows effectiveness against antibiotic-resistant bacteria. 5. Company aims to combat multi-drug resistant pathogens globally.

4m saved
Insight
Article

FAQ

Why Bullish?

The FDA approval of ORLYNVAH™ enhances Iterum's market position significantly. Historical approvals often lead to stock price increases due to heightened investor interest.

How important is it?

The article directly relates to ITRM's product and market strategy, highlighting key defensive and offensive advantages in pharma.

Why Long Term?

Long-term benefits expected from ongoing commercialization and market adoption of ORLYNVAH™. Historical precedent shows that successful drug launches can positively influence stock value over extended periods.

Related Companies

AMGNMRKPFEJNJ
April 14, 2025 08:00 ET  | Source: Iterum Therapeutics PLC DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that one poster was presented at the 35th Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) held in Vienna, Austria, from April 11-15, 2025. The poster presented at ECCMID was:  Title: Impact of age on antibiotic resistance and efficacy of antibiotics for women with uncomplicated urinary tract infection (uUTI)Presenting Author: Sailaja Puttagunta, MD Date: April 13, 2025   This Poster will be available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab. About Iterum Therapeutics plc Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com. About ORLYNVAH™ ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTI. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins. Investor Contact:Judy MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com 

Related News